Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17. April 2024 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe...
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
08. Januar 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...